Neurobiological Technologies Announces FDA Agreement To Consolidate Viprinex Phase 3 Trials Accelerating Time To Pivotal Data Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that following a meeting with the U.S. Food and Drug Administration to discuss the Viprinex(TM) (ancrod) Phase 3 clinical program for acute ischemic stroke, the company plans to consolidate and analyze data from its two concurrently running double-blind clinical trials into a single Phase 3 pivotal trial. This new plan will accelerate the timing of the trial's efficacy and safety data to mid-2009.
Source: www.medicalnewstoday.comHow Medicines Were Made On DVD - Royal Pharmaceutical Society Of Great Britain How
Medicines Were Made, a Society Museum film, is now available on DVD. First produced in 2001, the film shows retired community pharmacist Peter Homan demonstrating various techniques from the past, including pill-making, producing cachets (now an obsolete dosage form) and using a Brockedon press to make tablets.
Source: www.medicalnewstoday.comGSK Responds To NICE's 2nd Technology Appraisal Consultation Document On The Use Of Tyverb, In Combination With Capecitabine The draft recommendations announced today by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. "Given our involvement, it is difficult to comment without the appearance of self interest, however we strongly believe that the wrong decision has been made for patients, doctors and the NHS," said Simon Jose, General Manager for GSK UK Pharmaceuticals.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 PM
